NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Claudio Laudani: DOACs Have Transformed the Landscape of Anticoagulation
Claudio Laudani/X
Nov 18, 2025, 15:08

Claudio Laudani: DOACs Have Transformed the Landscape of Anticoagulation

Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:

”Direct oral anticoagulants (DOACs) have transformed the landscape of anticoagulation, offering more predictable pharmacology, improved safety, and easier management compared to vitamin K antagonists.

In this comprehensive review, we examine:

  • Pharmacokinetic and pharmacodynamic profiles of apixaban, rivaroxaban, dabigatran, and edoxaban.
  • Evidence supporting their use across atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and atherosclerosis compared with other antithrombotic strategies.
  • How to optimize DOAC therapy in vulnerable scenarios (renal impairment, elderly patients, perioperative management).
  • Remaining gaps and unmet clinical needs where further research is required, such as patients with rheumatic heart disease, mechanical heart valves, antiphospholipid syndrome, and patients with LVAD.”

Read the full article here.

Article: Safety and optimal use of direct oral anticoagulant therapy

Authors: Claudio Laudani, Luis Ortega-Paz, Ali Zgheib, Georges El Khoury, Mohmmad Alawajneh, Maryam Farahmandsadr, Davide Capodanno, Dominick J Angiolillo

Claudio Laudani: DOACs Have Transformed the Landscape of Anticoagulation

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.

Ali Zgheib Apixaban Claudio Laudani dabigatran Davide Capodanno Dominick J. Angiolillo edoxaban Georges El Khoury Health Hematology Hemostasis Hemostasis Today Luis Ortega-Paz LVAD Maryam Farahmandsadr Medicine Mohmmad Alawajneh Rivaroxaban thrombosis VKAs VTE
NewsFeed